Moderna (MRNA) Revenue (2017 - 2026)

Moderna has reported Revenue for 10 years, with the latest figure at $145.0 million in Q2 2026.

• Revenue for Q2 2026 came in at $145.0 million, up 2.11% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.2 billion (down 27.62% YoY), and the FY2025 annual result was $1.9 billion, down 39.93% from the prior year.
• Revenue eased to $145.0 million in Q2 2026, from $389.0 million in the prior quarter.
• Over five years, Revenue peaked at $6.1 billion in Q1 2022 and troughed at $108.0 million in Q1 2025.
• A 5-year average of $1.8 billion and a median of $991.0 million in 2024 frame the typical range for Revenue.
• The widest annual swing landed in 2023, when Revenue tumbled 92.76%; it then soared 260.19% in 2026.
• A 5-year view of Revenue shows it stood at $5.1 billion in 2022, then slumped by 44.71% to $2.8 billion in 2023, then tumbled by 65.64% to $966.0 million in 2024, then slipped by 29.81% to $678.0 million in 2025, then plunged by 78.61% to $145.0 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $145.0 million in Q2 2026, $389.0 million in Q1 2026, and $678.0 million in Q4 2025.